10-Q: Nordson Reports Mixed Q2 Results with Sales Growth Offset by Higher Costs and Interest Expense

Nordson Corporation announced its second-quarter fiscal 2025 results, showing a 5% increase in sales but a decline in net income and diluted earnings per share due to higher operating costs, interest expense, and foreign currency losses.

Summary

• Nordson Corporation reported sales of $682.9 million for the three months ended April 30, 2025, a 5.0% increase compared to $650.6 million in the same period last year.
• Net income for the quarter decreased by 4.9% to $112.4 million, down from $118.2 million in the prior year period.
• Diluted earnings per share (EPS) for the quarter were $1.97, a 3.9% decrease from $2.05 in the comparable period of 2024.
• For the six months ended April 30, 2025, sales increased by 1.1% to $1.298 billion, while net income decreased by 9.1% to $207.1 million, and diluted EPS fell by 8.4% to $3.62.
• Gross margin percentage declined to 54.7% for both the three and six-month periods, down from 56.2% and 55.6% respectively in the prior year.
• Operating profit remained relatively flat for the three months at $168.8 million but decreased by 5.6% to $309.7 million for the six months.
• Interest expense significantly increased by 32.1% for the quarter and 27.9% for the six months, primarily due to higher average debt levels from recent acquisitions.
• The Advanced Technology Solutions (ATS) segment showed strong organic sales growth of 18.1% for the quarter and 4.3% for the six months, driven by semiconductor and electronics demand, with operating margin improving by 4.5 percentage points.
• The Industrial Precision Solutions (IPS) segment experienced organic sales decreases of 6.9% for the quarter and 7.6% for the six months, mainly due to weaker systems demand in polymer processing and industrial coatings.
• The Medical and Fluid Solutions (MFS) segment saw a 20.0% total sales increase for the quarter (30.0% from acquisitions), but organic sales decreased by 10.0% due to targeted program rationalization and ongoing destocking in interventional product lines.
• The company completed the acquisition of Atrion Corporation on August 21, 2024, for $789.996 million, which contributed to MFS segment growth.
• Nordson's cash and cash equivalents increased by $14.2 million during the six months ended April 30, 2025, reaching $130.2 million.
• The company repurchased 423,521 common shares during the quarter ended April 30, 2025, at an average price of $201.49 per share, with $382.55 million remaining under the authorized repurchase program.
• A subsequent event on May 28, 2025, involves an agreement to divest select product lines within the medical contract manufacturing business, expected to close in Q4 fiscal 2025, with no material financial impact anticipated.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While sales increased, profitability metrics (net income, EPS, gross margin, operating profit for 6 months) declined. This was primarily driven by higher interest expense from acquisitions and significant foreign currency losses. Organic sales were mixed across segments, with two out of three experiencing declines. The strong liquidity position and strategic divestiture are positives, but the overall financial performance for the period is weaker than the prior year.

Positives

• Total sales increased by 5.0% for the three months and 1.1% for the six months ended April 30, 2025.
• The Advanced Technology Solutions (ATS) segment demonstrated strong organic sales growth of 18.1% for the quarter and 4.3% for the six months, driven by broad-based demand in semi-conductor and electronics end markets.
• ATS operating margin improved significantly by 4.5 percentage points for the quarter and 3.3 percentage points for the six months, benefiting from strong organic sales growth and strategic cost/manufacturing optimization.
• The Medical and Fluid Solutions (MFS) segment showed a 20.0% total sales increase for the quarter, largely due to the Atrion acquisition, and operating profit increased by $7.8 million.
• Nordson's liquidity position remains strong, with $130.2 million in cash and cash equivalents and $806.5 million in available borrowing capacity under loan agreements and unused bank lines of credit.
• The company is in compliance with all debt covenants as of April 30, 2025.
• The share repurchase program continues, with 423,521 shares repurchased in the quarter, indicating ongoing commitment to shareholder returns.

Negatives

• Net income decreased by 4.9% for the three months and 9.1% for the six months ended April 30, 2025.
• Diluted earnings per share (EPS) decreased by 3.9% for the three months and 8.4% for the six months.
• Gross margin percentage declined by 1.5 percentage points for the three months and 0.9 percentage points for the six months.
• Operating profit for the six months decreased by 5.6%, and consolidated operating margin declined by 1.7 percentage points, primarily due to reduced sales leverage.
• Interest expense increased substantially by 32.1% for the quarter and 27.9% for the six months, driven by higher average debt levels from acquisitions.
• Other expense (net) increased significantly by 404.6% for the quarter and 116.8% for the six months, largely due to foreign currency losses.
• The Industrial Precision Solutions (IPS) segment experienced organic sales declines of 6.9% for the quarter and 7.6% for the six months, attributed to weaker systems demand in polymer processing and industrial coatings.
• The Medical and Fluid Solutions (MFS) segment's organic sales decreased by 10.0% for the quarter and 10.6% for the six months, reflecting targeted program rationalization and ongoing customer destocking in interventional product lines.

Risks

• U.S. and international economic and political conditions could adversely affect business operations and financial results.
• Financial and market conditions, including interest rate fluctuations and credit availability, may impact the company's cost of capital and investment returns.
• Currency exchange rates and devaluations pose a risk to the translation of international sales and operating results into U.S. dollars, potentially impacting profitability.
• Challenges related to possible acquisitions and the company's ability to successfully integrate them, including the recent Atrion acquisition, could affect performance.
• The company's ability to successfully divest or dispose of businesses that do not fit its strategic plan may be impacted by market conditions or other factors.
• Changes in U.S. trade policy and trade agreements, including the imposition of tariffs by the U.S. or other nations, could negatively affect sales, margins, and profitability.
• Changes in tax law could impact the company's effective tax rate and overall financial results.
• Events beyond the company's control, such as political unrest (including conflicts in Europe and the Middle East), acts of terror, natural disasters, and pandemics, could disrupt operations and financial performance.

Future Outlook

Nordson expects to continue leveraging its scalable growth framework to deliver top-tier growth with leading margins and returns. The company anticipates that cash from operations, combined with available borrowing capacity and access to capital markets, will be more than adequate to fund liquidity needs for the next twelve months and the foreseeable future. The recent Atrion acquisition is not expected to materially impact consolidated financial statements, and the planned divestiture of certain medical contract manufacturing product lines in Q4 fiscal 2025 is also not anticipated to have a material impact, allowing the company to focus on proprietary medical components. The company is evaluating the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) with anticipated adoption in fiscal 2026 and 2028, respectively, and expects ASU 2023-07 to expand disclosures without impacting financial statements.

Management Comments

• Management believes the company is well-positioned to manage liquidity needs arising from working capital requirements, capital expenditures, and pension/postretirement obligations.
• Management expects cash from operations, combined with available borrowing capacity and ready access to capital markets, to be more than adequate to fund liquidity needs over the next twelve months and the foreseeable future.
• The company believes it has the ability to generate and obtain adequate amounts of cash to meet its long-term needs for cash.
• The divestiture of select product lines within the medical contract manufacturing business will allow the company to focus on achieving above-market growth in its proprietary medical components, including devices from the recent Atrion acquisition.

Industry Context

Nordson operates across diverse end markets including industrial, medical, and advanced technology solutions. The strong performance in the Advanced Technology Solutions segment, particularly in semiconductor and electronics, aligns with broader industry trends of increasing demand in these high-tech sectors. Conversely, the organic declines in Industrial Precision Solutions (polymer processing, industrial coatings) and Medical and Fluid Solutions (medical contract manufacturing, interventional product destocking) suggest a mixed industrial environment, with some sectors facing headwinds or inventory adjustments. The strategic divestiture in medical contract manufacturing indicates a focus on higher-growth, proprietary segments within the medical industry, consistent with a trend towards specialization and value-added offerings.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or global benchmarks to assess results against industry standards. Therefore, a direct comparison is not possible based solely on the provided information.

Legal Proceedings

• The company is involved in pending or potential litigation regarding environmental, product liability, patent, contract, and employee matters arising from the normal course of business.
• The company has voluntarily agreed to share costs associated with the remediation of the City of New Richmond municipal landfill and the construction of a potable water delivery system.

Stakeholder Impact

• Shareholders: Impacted by decreased net income and diluted EPS, but also by ongoing share repurchase programs and dividend payments ($0.78 per share declared for both quarters).
• Employees: Affected by organizational changes, such as the transfer of the MCS division, and potential impacts from strategic divestitures.
• Customers: May experience changes in product offerings due to strategic divestitures and focus on proprietary medical components.
• Creditors: The company remains in compliance with all debt covenants, indicating a stable position for creditors despite increased debt levels due to acquisitions.

Next Steps

• The company plans to adopt ASU 2023-07 (Segment Reporting) beginning with its Annual Report on Form 10-K for the fiscal year ending October 31, 2025.
• The company anticipates adopting ASU 2023-09 (Income Taxes) in fiscal 2026.
• The company anticipates adopting ASU 2024-03 (Income Statement) in fiscal 2028.
• The divestiture of select product lines within the medical contract manufacturing business is expected to close in the fourth quarter of fiscal 2025.

Key Dates

Recommendation

Keywords

Precision Technology, Dispensing Systems, Adhesives, Coatings, Polymers, Sealants, Biomaterials, Fluid Control, Medical Devices, Semiconductor, Electronics, Industrial Coatings, Polymer Processing, Nonwovens, Packaging, Precision Agriculture, Atrion Acquisition, SEC Filing, 10-Q, Quarterly Report